Table 2 |
||||
|
Distribution of the rheumatoid arthritis patients according to the presence of anti-MCV, anti-CCP, and IgM-RF |
||||
|
Anti-CCP-positive (n = 80), number (percentage) |
Anti-CCP-negative (n = 76), number (percentage) |
|||
|
|
|
|||
|
Cutoff 20 U/mL |
Cutoff 28 U/mL |
Cutoff 20 U/mL |
Cutoff 28 U/mL |
|
|
|
||||
|
Anti-MCV |
||||
|
Positive |
75 (93.75) |
71 (88.75) |
14 (18.4) |
9 (11.8) |
|
Negative |
5 (6.25) |
9 (11.25) |
62 (81.6) |
67 (88.2) |
|
RF+ |
||||
|
Anti-MCV+ |
65 (81.25) |
61 (76.25) |
5 (6.6) |
3 (3.9) |
|
Anti-MCV- |
1 (3.75) |
5 (6.25) |
8 (10.5) |
10 (13.2) |
|
RF- |
||||
|
Anti-MCV+ |
10 (12.5) |
10 (12.5) |
9 (11.8) |
6 (7.9) |
|
Anti-MCV- |
4 (5) |
4 (5) |
54 (71.1) |
57 (75) |
|
|
||||
|
Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor. |
||||
|
Nicaise Roland et al. Arthritis Research & Therapy 2008 10:R142 doi:10.1186/ar2570 |
||||
